(https://www.cnbc.com/2026/08/03/curium-strikes-up-to-8-billion-deal-for-radiopharma-peer-lantheus.html) — and nobody's asking the obvious question: why is big pharma paying premium valuations for bolt-on assets when their own pipelines should be generating organic growth? The deal screams desperation. Curium is betting that radiopharma fills a near-term revenue gap because traditional pharma organic growth is stalling.